Sunday November 22 2009 | Biotechnology feed | All feeds
|
|
Sunday November 22 2009 | Biotechnology feed | All feeds
|
|
|
PDE4 inhibitors for the treatment of atopic dermatitis PDE4 inhibitors have been the subject of intense pharmaceutical investigation for a number of years now. This therapeutic class is of particular use for the treatment of a variety of inflammatory diseases. For example PDE4 inhibitors were highlighted in our recent dossier "Therapeutic and pharmaceutical approaches to COPD" since the PDE4 inhibitor, cilomilast has some beneficial clinical effect in patients with either emphysema or bronchitis. This pharmaceutical class may also be of benefit to patients with atopic dermatitis. This pruritic inflammatory skin disease affects 10% of the population at some time in their life with about 60% of them continuing to have symptoms into adulthood. More than 15 million people have symptoms of the disease in the US alone. This condition often begins in infancy and frequently affects individuals with personal or family history of atopic disease. The world market for drugs to treat allergic diseases is a massive £10 billion and is growing at over 10% per annum. New products in current development offer little therapeutic advantage or improved patient compliance over existing therapy. German-based researchers have recently shown that two PDE4 inhibitors, cilomilast and AWD 12-281 are therapeutically active in a model of allergic dermatitis in mice. This study therefore offers proof supporting the concept that PDE4 inhibitors may be of use in the treatment of this disease.
Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
